Pardeep S. Jhund
YOU?
Author Swipe
View article: Obesity, aldosterone, and natriuretic peptides in patients with heart failure and reduced ejection fraction
Obesity, aldosterone, and natriuretic peptides in patients with heart failure and reduced ejection fraction Open
Aims Experimental evidence suggests that adipose tissue may secrete aldosterone, and mineralocorticoid receptor antagonists (MRAs) appear to be more effective in patients with obesity. Therefore, we examined aldosterone levels according to…
View article: Finerenone in patients with severe heart failure: The <scp>FINEARTS</scp> ‐ <scp>HF</scp> trial
Finerenone in patients with severe heart failure: The <span>FINEARTS</span> ‐ <span>HF</span> trial Open
Aims While patients with severe heart failure (HF) were historically considered to have reduced left ventricular ejection fraction (LVEF), it is increasingly recognized that severe HF occurs across the full spectrum of LVEF. The aim of thi…
View article: Finerenone in patients with severe heart failure: the FINEARTS-HF Trial
Finerenone in patients with severe heart failure: the FINEARTS-HF Trial Open
Background While patients with severe heart failure (HF) were historically considered to have reduced left ventricular ejection fraction (LVEF), it is increasingly recognized that severe HF exists regardless of LVEF, with patients experien…
View article: Patient Characteristics and Mortality Trends Among Octogenarians With Heart Failure
Patient Characteristics and Mortality Trends Among Octogenarians With Heart Failure Open
Over the past 2 decades, 2-year mortality rates in octogenarians with HF have improved despite an increase in comorbidities recorded at the time of diagnosis.
View article: Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction Open
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) and the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) finerenone have each been shown to individually improve heart failure events among patients with heart failure and mildly…
View article: #3019 Changes in albuminuria and the effect of finerenone on cardiovascular outcomes: insights from FINEARTS-HF
#3019 Changes in albuminuria and the effect of finerenone on cardiovascular outcomes: insights from FINEARTS-HF Open
Background and Aims Albuminuria reduction accounted for a modest proportion of the effect of finerenone in reducing adverse cardiovascular outcomes among patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). Wheth…
View article: Effect of Finerenone on Morbidity and Mortality in CKD
Effect of Finerenone on Morbidity and Mortality in CKD Open
Key Points In three trials, finerenone reduced a range of cardiovascular and kidney outcomes in persons with diabetes and CKD. Benefits of finerenone were observed across a broad spectrum of glycemia and kidney structure and function. In e…
View article: Composite endpoints in health technology assessment: Part 1 – an illustration of best modeling practice
Composite endpoints in health technology assessment: Part 1 – an illustration of best modeling practice Open
Composite endpoints amalgamate multiple clinical outcomes into a single measure, offering efficiency gains in clinical trials through increased event rates and reduced sample sizes, thus accelerating clinical development and regulatory app…
View article: Composite endpoints in health technology assessment: Part 2 – expanding the evidence base with a framework for best modeling practice
Composite endpoints in health technology assessment: Part 2 – expanding the evidence base with a framework for best modeling practice Open
The first paper of this two-part series critically examined the role of composite endpoints in health technology assessments (HTAs) and outlined strategies for determining whether to employ the composite estimate of treatment effect or dis…
View article: Finerenone according to insulin resistance in heart failure: Insights from the <scp>FINEARTS</scp>‐<scp>HF</scp> trial
Finerenone according to insulin resistance in heart failure: Insights from the <span>FINEARTS</span>‐<span>HF</span> trial Open
Aims The estimated glucose disposal rate (eGDR) is a simple, non‐invasive measure of insulin resistance. In this exploratory analysis of FINEARTS‐HF, we evaluated whether lower eGDR, reflecting greater insulin resistance, is associated wit…
View article: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial Open
Background and Aims The frequency and prognostic significance of abnormalities in serum magnesium concentrations have not been described in a contemporary HF population. The authors evaluated the prognostic significance of magnesium concen…
View article: Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure
Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure Open
Background and Aims The initiation of heart failure (HF) therapies at the time of detection of an elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) level in community-based patients with suspected HF may reduce the risk of ear…
View article: Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction Open
In a large HFmrEF/HFpEF trial population, clinically meaningful changes in readily available biomarkers, functional status, and patient-reported health status were observed in the months leading up to a clinical event. Monitoring these par…
View article: Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF
Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF Open
Aims To investigate the EQ-5D-3L Level Sum Score (LSS) in patients with heart failure (HF) and reduced (HFrEF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and the effect of sacubitril/valsartan on this score using pati…
View article: Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction Open
In patients with HFimpEF, the efficacy and safety of dapagliflozin in reducing cardiovascular death or worsening HF events were consistent irrespective of the degree of LVEF improvement before enrollment, including in those who achieve an …
View article: Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics
Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics Open
Importance Given their kidney actions, it is important to evaluate the efficacy and safety of mineralocorticoid receptor antagonists when combined with other diuretics and whether they have a so-called diuretic-sparing effect in patients w…
View article: Finerenone According to Frailty in Heart Failure
Finerenone According to Frailty in Heart Failure Open
Importance Patients with frailty are often perceived to have a less favorable benefit-risk profile for novel therapies and therefore may be less likely to receive these. Objective To examine the efficacy and safety of finerenone, compared …
View article: The crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the <scp>ESC</scp>
The crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the <span>ESC</span> Open
A better understanding of additional mechanisms of heart failure (HF) progression may allow a different and more complete phenotyping of the disease and identification of novel therapeutic targets. Persistent latent myocardial inflammation…
View article: Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance
Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance Open
Background The collection of race and ethnicity data in clinical trials using standardized categories is recommended by the US Food and Drug Administration, although this is primarily for domestic reasons. The applicability and understandi…
View article: Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure
Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure Open
Importance Vascular cell adhesion molecule 1 (VCAM-1) and intracellular cell adhesion molecule 1 (ICAM-1) are responsible for immune cell-cell interactions. Systemic levels of VCAM-1 are associated with incident heart failure (HF). Objecti…
View article: Finerenone in Heart Failure With Improved Ejection Fraction
Finerenone in Heart Failure With Improved Ejection Fraction Open
Importance Patients with chronic heart failure (HF) and left ventricular ejection fraction (LVEF) less than 40% who experience LVEF improvement to 40% or higher (HFimpEF) may still face residual risks. Objective To assess the clinical prof…
View article: Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the <scp>FINEARTS</scp>‐<scp>HF</scp> trial
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the <span>FINEARTS</span>‐<span>HF</span> trial Open
Aims Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the eff…
View article: Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The <scp>FINEARTS</scp>‐<scp>HF</scp> trial
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The <span>FINEARTS</span>‐<span>HF</span> trial Open
Aims: N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations serve as markers of prognosis and therapeutic response in patients with heart failure (HF). The effect of the non-steroidal mineralocorticoid receptor antagonist fi…